The in vivo effect of Type I interferon (IFN) can be prolonged by administering the interferon in the form of a complex with an IFN binding chain of the human interferon alpha / beta receptor (IFNAR). Such a complex also improves the stability of the IFN and enhances the potency of the IFN. The complex may be a non-covalent complex or one in which the IFN and the IFNAR are bound by a covalent bond or a peptide. When bound by a peptide bond in the form of a fusion protein, the IFN may be separated from the IFNAR by means of a peptide linker. Such a fusion protein may be produced by recombinant DNA technology. Storing IFN in the form of such a complex improves the storage life of the IFN and permits storage under milder conditions than would otherwise be possible.
申请公布号
WO9932141(A1)
申请公布日期
1999.07.01
申请号
WO1998US26926
申请日期
1998.12.18
申请人
APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.;MCINNIS, PATRICIA, G.
发明人
TEPPER, MARK;CUNNINGHAM, MARK;SHERRIS, DAVID;EL TAYAR, NABIL;MCKENNA, SEAN